Navigation Links
Halting Bone-Building Osteoporosis Drug Use Cuts Risk for Additional Atypical Femur Fracture in Half
Date:2/8/2012

SAN FRANCISCO, Feb. 8, 2012 /PRNewswire-USNewswire/ -- There is growing evidence that supports an association between atypical fractures of the femur – a rare break of the thigh bone, typically without trauma – and the use of bisphosphonates, drugs proven to enhance bone density and reduce fracture incidence caused by osteoporosis. While the risk for suffering an atypical femur fracture while taking bisphosphonates is still very small – just 1 in 1,000 patients after six years of treatment – research presented today at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) found that discontinuing bisphosphonate use following an atypical femur fracture can significantly lower the risk for a subsequent atypical fracture.

Scientists believe that bisphosphonates may suppress the body's natural process of remodeling – where old bone tissue is replaced with new, healthy tissue – in some patients, resulting in brittle bones susceptible to atypical fractures, especially in the femur.

Investigators reviewed femur fracture data from Jan. 1, 2007 until Dec. 31, 2009 in patients older than 45 enrolled in a large California HMO. There were 126 patients with an atypical femur fracture who reportedly took bisphosphonates prior to their bone break.

The incidence of a subsequent atypical femur fracture occurring in the other thigh was 53.9 percent in patients who continued bisphosphonates for three or more years after their first fracture, compared to 19.3 percent in patients who discontinued bisphosphonate use. Overall, subsequent atypical femur fractures were decreased by 65.6 percent when bisphosphonates were stopped within one year following the first fracture.

"The risk of a contralateral atypical femur fracture (on the opposite side) increases over time if the bisphosphonates are continued," said lead investigator Richard Dell, MD, a researcher in the Department of Orthopaedics at Kaiser Permanente. "Based on these observations, we recommend discontinuing bisphosphonate use as soon as possible after the initial atypical femur fracture has occurred."  

Dr. Dell then recommends the ongoing evaluation of these patients, through X-ray or MRI, as they still are at risk for a subsequent, atypical femur fracture on the other femur.

If the patient is at high risk for other fractures, the study recommends use of an alternative osteoporosis medication.

Disclosure:  The author of this study does not have anything related to disclose.

Study Abstract

About  AAOS

Follow us on Facebook.com/AAOS1 and Twitter.com/AAOS1

For more information on bone and joint health, visit Orthoinfo.org.


'/>"/>
SOURCE American Academy of Orthopaedic Surgeons
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015
2. Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
3. Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis
4. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
5. Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
6. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
7. Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis
8. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
9. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
10. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
11. Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... URBANDALE, Iowa , Jan. 18, 2017 /PRNewswire/ ... announced that subsidiary Caretta Therapeutics plans, in the ... product. Venodol, a topical roll-on intended to provide ... to opioid and steroidal analgesics. It was developed ... Reid to commercialize products derived from snake ...
(Date:1/18/2017)... , Jan. 18, 2017  Kratom leaves, from ... family, are often used to prepare tea-like beverages ... several million Americans annually to increase alertness, enhance ... remedy for minor aches and pains. PinneyAssociates, review ... intended to assist FDA and DEA in determining ...
(Date:1/18/2017)... 18, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, announces dosing the ... a Phase 2 acne rosacea study. DMT210 is ... proinflammatory cytokines in the skin responsible for the ... This clinical trial, DMT210-003, is a ...
Breaking Medicine Technology:
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... Health, is now offering treatments for patients with sleep apnea and TMJ disorders. ... for dental and physical health. Dr. Rassouli provides personalized care to reduce the ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance Agency, a full ... clients in the California Bay Area, is launching a charity drive to raise awareness ... Heart disease is the primary killer of adult men and women in America, and ...
(Date:1/19/2017)... ... January 19, 2017 , ... St. Catherine’s Village announced that a limited ... a skilled nursing facility on the grounds of the St. Catherine’s Village campus in ... voted the best nursing home in Mississippi for the second year in a row ...
(Date:1/19/2017)... ... , ... The CHP suggests that California drivers can avoid hydroplaning as well ... increasing the space between themselves and other vehicles, according to a January 3 ... Hassanlou notes that, rain or shine, drivers should always incorporate safe driving practices in ...
(Date:1/19/2017)... ... , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, announced today ... past 20 years SFI has been recognized as the world’s leader in Intelligent Sales ... the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, Stress Pal, ...
Breaking Medicine News(10 mins):